BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $600276.SS readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05884255-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~Lutetium (177Lu) Oxodotreotide Injection；long-act… readout (P3
 ) · Jiangsu HengRui Medicine Co.\, Ltd. $600276.SS
DESCRIPTION:An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide I
 njection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocr
 ine Tumors.\n\nPrimary completion date: 2026-12 (estimated) — month only
 \, shown on the 1st\nPhase 3 · Oncology · Advanced Gastroenteropancreati
 c Neuroendocrine Tumor\nEnrollment: 220 · Sites: 2\n\nPrimary completion 
 = last participant's primary-endpoint data collected\; topline results usu
 ally follow weeks to months later. Sponsor-reported\, often an estimate. N
 ot investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05884255
 \nhttps://clinicaltrials.gov/study/NCT05884255
URL:https://datacutoff.com/radar.html?nct=NCT05884255
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472725-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~SHR-3167 Injection readout (P2) · Jiangsu HengRui Medicine Co.\, 
 Ltd. $600276.SS
DESCRIPTION:A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Ti
 tration and Individualized-Dose Titration in Adults With Type 2 Diabetes I
 nadequately Controlled With Oral Antihyper…\n\nPrimary completion date: 
 2026-12 (estimated) — month only\, shown on the 1st\nPhase 2 · Cardio-M
 et · Diabetes Mellitus\, Type 2\nEnrollment: 102 · Sites: 2\n\nPrimary c
 ompletion = last participant's primary-endpoint data collected\; topline r
 esults usually follow weeks to months later. Sponsor-reported\, often an e
 stimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=N
 CT07472725\nhttps://clinicaltrials.gov/study/NCT07472725
URL:https://datacutoff.com/radar.html?nct=NCT07472725
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04957550-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261213
DTEND;VALUE=DATE:20261214
SUMMARY:SHR0302 tablets、Placebo readout (P3) · Jiangsu HengRui Medicine 
 Co.\, Ltd. $600276.SS
DESCRIPTION:To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjec
 ts of Active Psoriatic Arthritis\n\nPrimary completion date: 2026-12-13 (e
 stimated)\nOriginally planned: 2023-11-13 (+37.0 months)\nPhase 3 · Immun
 o · Psoriatic Arthritis\nEnrollment: 418 · Sites: 1\n\nPrimary completio
 n = last participant's primary-endpoint data collected\; topline results u
 sually follow weeks to months later. Sponsor-reported\, often an estimate.
  Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT049575
 50\nhttps://clinicaltrials.gov/study/NCT04957550
URL:https://datacutoff.com/radar.html?nct=NCT04957550
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04691804-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fuzuloparib \, Abiraterone acetate and Prednisone readout (P3) · J
 iangsu HengRui Medicine Co.\, Ltd. $600276.SS
DESCRIPTION:A Multicenter\, Randomized\, Double-Blind\, Placebo-Controlled 
 Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Predn
 isone (AA-P) Versus Placebo Combined With AA-…\n\nPrimary completion dat
 e: 2026-12-31 (estimated)\nPhase 3 · Oncology · Metastatic Castration-Re
 sistant Prostate Cancer (mCRPC)\nEnrollment: 496 · Sites: 147\n\nPrimary 
 completion = last participant's primary-endpoint data collected\; topline 
 results usually follow weeks to months later. Sponsor-reported\, often an 
 estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=
 NCT04691804\nhttps://clinicaltrials.gov/study/NCT04691804
URL:https://datacutoff.com/radar.html?nct=NCT04691804
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05424835-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-A1811 readout (P3) · Jiangsu HengRui Medicine Co.\, Ltd. $6002
 76.SS
DESCRIPTION:A Trial of SHR-A1811versus Pyrotinib in Combination With Capeci
 tabine in HER2-Positive\, Unresectable and/or Metastatic Breast Cancer Sub
 jects Previously Treated With Trastuzumab a…\n\nPrimary completion date:
  2026-12-31 (estimated)\nOriginally planned: 2024-12-31 (+24.0 months)\nPh
 ase 3 · Oncology · HER2-Positive\, Unresectable and/or Metastatic Breast
  Cancer…\nEnrollment: 381 · Sites: 1\n\nPrimary completion = last parti
 cipant's primary-endpoint data collected\; topline results usually follow 
 weeks to months later. Sponsor-reported\, often an estimate. Not investmen
 t advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05424835\nhttps://cl
 inicaltrials.gov/study/NCT05424835
URL:https://datacutoff.com/radar.html?nct=NCT05424835
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413745-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-A1811 readout (P2) · Jiangsu HengRui Medicine Co.\, Ltd. $6002
 76.SS
DESCRIPTION:Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expr
 ession / Amplification of Locally Advanced Unresectable or Recurrent Metas
 tatic Biliary Tract Cancer\n\nPrimary completion date: 2026-12-31 (estimat
 ed)\nOriginally planned: 2025-09 (+16.0 months)\nPhase 2 · Oncology · HE
 R2 Expression / Amplification in Patients With Biliary Tr…\nEnrollment: 
 59 · Sites: 1\n\nPrimary completion = last participant's primary-endpoint
  data collected\; topline results usually follow weeks to months later. Sp
 onsor-reported\, often an estimate. Not investment advice.\n\nhttps://data
 cutoff.com/radar.html?nct=NCT06413745\nhttps://clinicaltrials.gov/study/NC
 T06413745
URL:https://datacutoff.com/radar.html?nct=NCT06413745
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746726-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-9190 readout (P3) · Jiangsu HengRui Medicine Co.\, Ltd. $60027
 6.SS
DESCRIPTION:Safety and Efficacy of HRS-9190 Compared to Rocuronium for Trac
 heal Intubation and Bolus Maintenance in Adults\n\nPrimary completion date
 : 2026-12-31 (estimated)\nPhase 3 · Other · Neuromuscular Blockade\nEnro
 llment: 320 · Sites: 2\n\nPrimary completion = last participant's primary
 -endpoint data collected\; topline results usually follow weeks to months 
 later. Sponsor-reported\, often an estimate. Not investment advice.\n\nhtt
 ps://datacutoff.com/radar.html?nct=NCT07746726\nhttps://clinicaltrials.gov
 /study/NCT07746726
URL:https://datacutoff.com/radar.html?nct=NCT07746726
CATEGORIES:Other,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241416-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~Rezvilutamide Tablets readout (P3) · Jiangsu HengRui Medicine Co.
 \, Ltd. $600276.SS
DESCRIPTION:A Phase III Clinical Study of Rezvilutamide in Patients With Me
 tastatic Hormone-Sensitive Prostate Cancer\n\nPrimary completion date: 202
 7-03 (estimated) — month only\, shown on the 1st\nPhase 3 · Oncology ·
  Metastatic Hormone-sensitive Prostate Cancer (mHSPC)\nEnrollment: 206 · 
 Sites: 1\n\nPrimary completion = last participant's primary-endpoint data 
 collected\; topline results usually follow weeks to months later. Sponsor-
 reported\, often an estimate. Not investment advice.\n\nhttps://datacutoff
 .com/radar.html?nct=NCT07241416\nhttps://clinicaltrials.gov/study/NCT07241
 416
URL:https://datacutoff.com/radar.html?nct=NCT07241416
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07251595-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~SHR0302 Tablets readout (P2) · Jiangsu HengRui Medicine Co.\, Ltd
 . $600276.SS
DESCRIPTION:A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients Wit
 h Non-segmental Vitiligo\n\nPrimary completion date: 2027-03 (estimated) 
 — month only\, shown on the 1st\nPhase 2 · Immuno · Non-segmental Viti
 ligo\nEnrollment: 176 · Sites: 1\n\nPrimary completion = last participant
 's primary-endpoint data collected\; topline results usually follow weeks 
 to months later. Sponsor-reported\, often an estimate. Not investment advi
 ce.\n\nhttps://datacutoff.com/radar.html?nct=NCT07251595\nhttps://clinical
 trials.gov/study/NCT07251595
URL:https://datacutoff.com/radar.html?nct=NCT07251595
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06828354-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~SHR-A1811 readout (P3) · Jiangsu HengRui Medicine Co.\, Ltd. $600
 276.SS
DESCRIPTION:A Study of SHR-A1811 in Subjects With Ovarian Cancer\n\nPrimary
  completion date: 2027-05 (estimated) — month only\, shown on the 1st\nP
 hase 3 · Oncology · Ovarian Cancer\nEnrollment: 300 · Sites: 2\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?n
 ct=NCT06828354\nhttps://clinicaltrials.gov/study/NCT06828354
URL:https://datacutoff.com/radar.html?nct=NCT06828354
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03980054-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~Pyrotinib readout (P3) · Jiangsu HengRui Medicine Co.\, Ltd. $600
 276.SS
DESCRIPTION:A Study of Evaluating The Effects Of Pyrotinib After Adjuvant T
 rastuzumab In Women With Early Stage Breast Cancer\n\nPrimary completion d
 ate: 2027-06 (estimated) — month only\, shown on the 1st\nOriginally pla
 nned: 2022-07-31 (+58.0 months)\nPhase 3 · Oncology · Breast Cancer\nEnr
 ollment: 2135 · Sites: 1\n\nPrimary completion = last participant's prima
 ry-endpoint data collected\; topline results usually follow weeks to month
 s later. Sponsor-reported\, often an estimate. Not investment advice.\n\nh
 ttps://datacutoff.com/radar.html?nct=NCT03980054\nhttps://clinicaltrials.g
 ov/study/NCT03980054
URL:https://datacutoff.com/radar.html?nct=NCT03980054
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362355-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~SHR4640 ；Febuxostat readout (P2) · Jiangsu HengRui Medicine Co.
 \, Ltd. $600276.SS
DESCRIPTION:The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg F
 ebuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia\n\nPr
 imary completion date: 2027-07 (estimated) — month only\, shown on the 1
 st\nPhase 2 · Other · Primary Gout and Hyperuricemia\nEnrollment: 340 ·
  Sites: 1\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://datacutof
 f.com/radar.html?nct=NCT07362355\nhttps://clinicaltrials.gov/study/NCT0736
 2355
URL:https://datacutoff.com/radar.html?nct=NCT07362355
CATEGORIES:Other,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003321-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~HRS-4508 tablet readout (P2) · Jiangsu HengRui Medicine Co.\, Ltd
 . $600276.SS
DESCRIPTION:A Trial of HRS-4508 in Subjects With Locally Advanced or Metast
 atic Non-small Cell Lung Cancer\n\nPrimary completion date: 2027-09 (estim
 ated) — month only\, shown on the 1st\nPhase 2 · Oncology · Solid Tumo
 r\nEnrollment: 120 · Sites: 1\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://datacutoff.com/radar.html?nct=NCT07003321\nhttps://clinicaltri
 als.gov/study/NCT07003321
URL:https://datacutoff.com/radar.html?nct=NCT07003321
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07920939-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:~SHR-3167 Injection readout (P3) · Jiangsu HengRui Medicine Co.\, 
 Ltd. $600276.SS
DESCRIPTION:Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-
 Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes\n\nPri
 mary completion date: 2027-10 (estimated) — month only\, shown on the 1s
 t\nPhase 3 · Cardio-Met · Type 2 Diabetes\nEnrollment: 450 · Sites: 2\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar
 .html?nct=NCT07920939\nhttps://clinicaltrials.gov/study/NCT07920939
URL:https://datacutoff.com/radar.html?nct=NCT07920939
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06775340-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~RSS0343 Tabella readout (P2) · Jiangsu HengRui Medicine Co.\, Ltd
 . $600276.SS
DESCRIPTION:Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis B
 ronchiectasis\n\nPrimary completion date: 2027-11 (estimated) — month on
 ly\, shown on the 1st\nOriginally planned: 2025-11 (+24.0 months)\nPhase 2
  · Respiratory · Adolescent Asthma\nEnrollment: 252 · Sites: 1\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?n
 ct=NCT06775340\nhttps://clinicaltrials.gov/study/NCT06775340
URL:https://datacutoff.com/radar.html?nct=NCT06775340
CATEGORIES:Respiratory,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241767-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~FH-006 \; SHR-1316 \; BP102 \; Cisplatin \; Carboplat… readout (
 P2) · Jiangsu HengRui Medicine Co.\, Ltd. $600276.SS
DESCRIPTION:A Phase II Clinical Study of FH-006 for Injection Combined With
  Other Anticancer Therapies in Subjects With Lung Cancer\n\nPrimary comple
 tion date: 2027-11 (estimated) — month only\, shown on the 1st\nPhase 2 
 · Oncology · Lung Cancer\nEnrollment: 200 · Sites: 1\n\nPrimary complet
 ion = last participant's primary-endpoint data collected\; topline results
  usually follow weeks to months later. Sponsor-reported\, often an estimat
 e. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0724
 1767\nhttps://clinicaltrials.gov/study/NCT07241767
URL:https://datacutoff.com/radar.html?nct=NCT07241767
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
